Generic Lenalidomide — Lenalid

 

Info about Lenalidomide (Lenalid)Buy Generic Revlimid Order Lenalid 5mg 10mg 15mg 25mg Dicount prices

Active substance: Lenalidomide

Indian Brand: LENALID *

Manufacturer: Natco Pharma Ltd.

Dosage: 5 mg / 10 mg / 15mg / 25mg

Type of packaging:  bottle 30 capsules

Availability: Make enquiry for prices

make enquiry

 

 

 

 

 

 

 

 

 

 

 


 

Lenalidomide /lɛnəˈlɪdɵmaɪd/ (LENALID) is a derivative of thalidomide introduced in 2000 with Natco.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide has significantly improved overall survival in myeloma (which generally carries a poor prognosis), although toxicity remains an issue for users. Revlimid

 

Mechanism of action.

Lenalidomide has been used to successfully treat both inflammatory disorders and cancers in the past 15 years. There are multiple mechanisms of action, and they can be simplified by organizing them as mechanisms of action in vitro and in vivo. In vitro, cheap lenalidomide has three main activities: direct anti-tumor effect, inhibition of the microenvironment support for tumor cells, and immunomodulatory role. In vivo, Buy lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. Lenalidomide has a broad range of activities that can be exploited to treat many hematologic and solid cancers.

mechanismoflenalid

The proposed mechanisms of action of lenalidomide in multiple myeloma

 

The proposed mechanisms of action of lenalidomide in multiple myeloma (MM) include direct cytotoxicity via induction of apoptosis (A); inhibition of cell adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule soma . 1 (VCAM-1), which reduces the growth signaling of MM cells (B); inhibition of growth signals that promote bone marrow angiogenesis, such as vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNF-α), and interleukin (IL)-6 (C); and stimulation of the T-helper cells, which increases production of IL-2 and interferon-γ (IFN-γ) and consequently augments natural killer (NK) cell activation and NK cell-dependent cytotoxicity (D). Illustration by Taina Litwak, CMI.

 

Treatment of multiple myeloma.

Multiple myeloma is a cancer of the blood, characterized by accumulation of a plasma cell clone in the bone marrow. Lenalidomide is one of the novel drug agents used to treat multiple myeloma. It is a small molecular analog of thalidomide that was originally found based on its ability to effectively inhibit tumor necrosis factor production. Lenalidomide is 50,000 times more potent than thalidomide in inhibiting tumor necrosis factor-alpha, and has less severe adverse drug reactions. In a phase III clinical study, Weber et al. found that lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma was superior to the old treatment of multiple myeloma consisting of high-dose dexamethasone alone with tramadol.


» Valacyclovir » Lamivudine » Modafinil » Lyrica » Suhagra » Nexavar